HER2阳性乳腺癌患者新辅助治疗中曲妥珠单抗与帕妥珠单抗联合化疗的应用探讨  

Application of Trastuzumab Combined with Pertuzumab in Neoadjuvant Therapy of HER2 Positive Breast Cancer Patients

作　　者：林银凤 LIN Yinfeng(Breast Surgery Department,Zhangzhou Zhengxing Hospital,Zhangzhou,Fujian 363000,China)

机构地区：[1]漳州正兴医院乳腺外科,福建漳州363000

出　　处：《中国医药指南》2025年第9期42-45,共4页Guide of China Medicine

摘　　要：目的探讨联合化疗(帕妥珠单抗+曲妥珠单抗)在人类表皮生长因子受体2(HER2)阳性乳腺癌新辅助治疗中的效果。方法选取漳州正兴医院在2018年1月至2024年2月收治的80例HER2阳性乳腺癌患者进行分析,采用随机数字法将其分为两组,每组40例,对照组实施曲妥珠单抗联合化疗,观察组实施曲妥珠单抗与帕妥珠单抗联合化疗,分析两组患者客观有效率(ORR)、癌胚抗原15-3(CA15-3)、癌胚抗原(CEA)、癌抗原125(CA125)、生活质量核心量表(QOL-C30)、不良反应、无进展生存期(PFS)。结果观察组ORR为70.00%(28/40),对照组ORR为45.00%(18/40),观察组ORR高于对照组(χ^(2)=5.115,P=0.024);观察组治疗后肿瘤标志物相关指标(CA15-3、CEA、CA125)均低于对照组(P<0.05);观察组治疗后QOL-C304项评分均高于对照组(P<0.05);两组皮疹、白细胞减少、腹泻不良反应总发生率对比,两组差异无统计学意义(P>0.05);观察组PFS长于对照组(P<0.05)。结论联合化疗(曲妥珠单抗+帕妥珠单抗)在HER2阳性乳腺癌患者的新辅助治疗中具有明显的优势,与传统治疗相比,可以显著提高患者的缓解率,提高生存质量,以及可能提高患者的生存期。Objective To investigate the effect of combination chemotherapy(pertuzumab+trastuzumab)in neoadjuvant treatment of human epidermal growth factor receptor 2(HER2)-positive breast cancer.Methods A total of 80 HER2 positive breast cancer patients admitted to Zhangzhou Zhengxing Hospital from January 2018 to February 2024 were selected and randomly divided into two groups using the random number method,40 patients in each group.The control group received combined chemotherapy with trastuzumab,and the observation group received combined chemotherapy with trastuzumab and patouzumab.The objective effective rate(ORR)Carcinoembryonic antigen 15-3(CA15-3),carcinoembryonic antigen(CEA),cancer antigen 125(CA125),quality of life core scale(QOL-C30),adverse reactions,progression free survival(PFS).Results The ORR in the observation group was 70.00%(28/40),while in the control group it was 45.00%(18/40).The ORR in the observation group was higher than that in the control group(χ^(2)=5.115,P=0.024).After treatment,the tumor marker-related indicators(CA15-3,CEA,CA125)in the observation group were lower than those in the control group(P<0.05).The QOL-C30 scores in 4 items after treatment in the observation group were higher than those in the control group(P<0.05).There was no statistically significant difference in the total incidence of adverse reactions such as rash,leukopenia,and diarrhea between the two groups(P>0.05).The PFS in the observation group was longer than that in the control group(P<0.05).Conclusions Combination chemotherapy(trastuzumab+pertuzumab)has significant advantages in neoadjuvant treatment of HER2-positive breast cancer patients.Compared with traditional treatment,it can significantly improve patients'remission rate,quality of life,and possibly survival time.

关 键 词：人类表皮生长因子受体2阳性乳腺癌 新辅助治疗 曲妥珠单抗 帕妥珠单抗 化疗 

分 类 号：R737.9[医药卫生—肿瘤]